Investor Presentaiton

Top-tier talent Differentiated process Scalable platform Exhaustive due diligence process sharpened over decades • NIN Clinical • • • Commercial Regulatory, IP, Manufacturing Intellectual property US/EU/Japan and other Multiple opinions Manufacturing Modality expertise: small molecule, biologics, gene therapy Claims analysis Patient diagnosis, treatment, compliance • Site of care Other patient metrics US pricing Pricing modeling • Gross-to-net modeling • Litigation scenario analysis • • Regulatory perspectives • Capacity planning Competition Landscape analysis Market sizing • • • Patient finding Claims-driven Epidemiology Scaled market surveys Payors • • Payor/PBM executives Formulary analyses International access Market-by-market pricing 良 Contracts, Governance Transactional Accounting treatment • Tax implications Licensing and contracts Analysis of contract language ⚫ Risk assessment Expert structuring and drafting Management & Physician diligence • US/EU/Japan • KOL/academic Community Surveys Statistics • Probability of success Effect size modeling Enrollment modeling Statistical Analysis Plans Clinical Non-clinical • Pharmacokinetics Pharmacodynamics • Dose modeling Toxicology Animal toxicologists • Specialized areas - (i.e., ophthalmology) • Interview former R&D executives • Patient level data analysis • Immunogenicity and specific safety observations • Clinical trial design and study reports • Comparative analysis • Patients & Caregivers Efficacy, tolerability, convenience perspectives Social media ROYALTY PHARMA Drug delivery • Design and human factors Formulation technologies Regulatory • • US/FDA meeting minutes EU/EMA meeting minutes International (PMDA, other) • Consultants Commercial strategy • Interview sales and marketing executives, MSLs and district managers • Required promotional spend Environmental, Social & Governance • Board oversight ESG-informed investment processes US: United States; EU: European Union; KOL: key opinion leader; FDA: Food & Drug Administration; EMA: European Medicines Agency; PBM: pharmacy benefit managers; MSL: medical science liaison; PMDA: Pharmaceuticals and Medical Devices Agency; ESG: environmental, social and governance; IP: intellectual property • Auto-injectors and devices governance • • Product profile and cost comparisons • Addressable patients • Yearly access caps and other structures • Experience and strategy Compensation alignment 55

View entire presentation